Low-dose chemotherapy

Low-dose chemotherapy is a type of chemotherapy that uses lower doses of chemotherapeutic drugs than standard chemotherapy. The goal of low-dose chemotherapy is to minimize the side effects of treatment while still effectively controlling the growth of cancer cells.

Overview

Low-dose chemotherapy, also known as metronomic chemotherapy, is a treatment strategy that involves giving patients smaller doses of chemotherapy drugs over a longer period of time. This approach is different from standard chemotherapy, which typically involves giving patients high doses of drugs in cycles, with breaks in between to allow the body to recover.

The idea behind low-dose chemotherapy is to minimize the side effects of treatment, which can include nausea, vomiting, hair loss, and fatigue, among others. By using lower doses of drugs, doctors hope to reduce these side effects while still effectively controlling the growth of cancer cells.

Mechanism of action

The mechanism of action of low-dose chemotherapy is not fully understood. However, it is thought that low-dose chemotherapy may work by targeting the endothelial cells that line the blood vessels supplying tumors, rather than the tumor cells themselves. This could potentially starve the tumor of nutrients and oxygen, slowing its growth.

Efficacy

The efficacy of low-dose chemotherapy is still a topic of ongoing research. Some studies have suggested that low-dose chemotherapy may be as effective as standard chemotherapy for certain types of cancer, while others have found that it may be less effective.

Side effects

The side effects of low-dose chemotherapy are generally less severe than those of standard chemotherapy. However, patients may still experience side effects such as fatigue, nausea, and hair loss. The severity of these side effects can vary widely from patient to patient.

See also

• Chemotherapy
• Cancer
• Oncology

Low-dose chemotherapy Resources
Need Help Finding a Doctor? WikiMD's DocFinder can help find general and specialist physicians.	Latest articles Most recent articles Ongoing trials.